@prefix this: <http://purl.org/np/RA7c3GCa41MjE_j49anVxoxDkq41xz1YzI2cwz4HYfzCc> .
@prefix sub: <http://purl.org/np/RA7c3GCa41MjE_j49anVxoxDkq41xz1YzI2cwz4HYfzCc#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_13189> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_13189>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00503>;
    a rdf:Statement;
    rdfs:label "\"* When co-administering ritonavir with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information.  Table 2. Drugs that are Contraindicated with Ritonavir           Drug Class   Drugs Within Class That Are Contraindicated With Ritonavir **   Clinical Comments   Alpha 1 Alfuzosin HCL Potential for hypotension.      Antianginal  Ranolazine  Potential for serious and/or life-threatening reactions.       Antiarrhythmic Amiodarone,dronedarone, flecainide, propafenone, Potential for cardiac arrhythmias.    Antifungal  Voriconazole Voriconazole is contraindicated with ritonavir doses of 400 mg every 12 hours or greaterdue to the potential for loss of antifungal response.    Anti-gout Colchicine a Potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment.   Antipsychotics Lurasidone Potential for serious and/or life-threatening reactions.   Ergot Derivatives Dihydroergotamine,  Potential for acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.   GI Motility Agent  Cisapride Potential for cardiac arrhythmias.   Herbal Products  St. John's Wort (hypericum perforatum) May lead to loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors.   HMG-CoA Reductase Inhibitors:  Lovastatin, simvastatin Potential for myopathy including rhabdomyolysis.   PDE5 inhibitor Sildenafil b (r) Potential for sildenafil-associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope.   Sedative/hypnotics  Oral midazolam c Prolonged or increased sedation or respiratory depression.     a   7 Table 5 b   7 Table 5 c   ( 7 Table 5 * Ritonavir is contraindicated in patients with known hypersensitivity to ritonavir (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome) or any of its ingredients (4)\"";
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB00503> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "GmI30THx9Vq0z7IBrLuns3C3WWU5iaMKTYz4MWQFl3Dc05t+hAZBEVyIQnSeGs1urg3PZS/6Y/RGjK2VyrwEjHERGPAn5oQ+ZyXVTWT0ECy5qev3375wwexLN1vPbN362MUt30Ya9N6WMQ/CnT2eWN5JR5kXEr1HptdQWJuIIhs=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-23T12:50:29.916+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}